INTRODUCTION {#s1}
============

A large number of populations suffer from bladder cancer which resulted in 380,000 cases and 150,000 deaths over the world in 2008 \[[@R1]\]. Bladder cancer is classified as either muscle-invasive bladder cancer (MIBC) or non-muscle-invasive bladder cancer (NMIBC) according to disease severity (high or low) and the extent of permeation \[[@R2]\]. Approximately 70% of bladder cancers are NMIBC which can be further classified into carcinoma-in-situ (CIS), papillary tumor (Ta) and those that are able to invade the lamina propria rather than the detrusor muscle (T1) \[[@R3]\]. Transurethral resection (TUR) is a standard treatment for NMIBC \[[@R4]\]. However, patients treated with TUR are often accompanied with a high tumor recurrence (TR) rate ranging from 50% to 70% as well as a high tumor progression (TP) rate between 10% and 20% over a period of 2--5 years \[[@R5], [@R6]\]. Hence, a few intravesical therapies which instill chemotherapeutic agents into bladder have been developed to supplement TUR.

Bacille Calmette-Guerin (BCG) is one of the most popular chemotherapeutic agents that have been incorporated into intravesical therapies. Adjuvant treatments such as intravesical instillations of BCG are appropriate for those NMIBC patients with a high risk of recurrence \[[@R4], [@R7]\]. Unfortunately, about one third of NMIBC patients eventually experience side effects resulted from BCG, including mild dysuria \[[@R8]\]. Recently, mytomicin C (MMC) is introduced into intravesical therapies in order to overcome the corresponding side effects \[[@R9]\]. MMC is effective for non-severe bladder cancer and it is usually administered by using multiple infusions which is able to produce response rates ranging between 40% and 50% \[[@R6]\].

Apart from the above mentioned chemotherapeutic agents, epirubicin (EPI) is another one which is applied in conjunction with intravesical therapies and the popularity of EPI has been increased in the Europe and Japan \[[@R10]\]. EPI belongs to the anthracyclines family and it was developed to reduce adverse effects resulted from chemotherapeutic agents without significant compensation of antitumor effects \[[@R11]\]. Antitumor effects are triggered by EPI which is able to interfere with DNA synthesis and EPI is associated with a relatively low risk of side effects particularly in patients with Ta or T1 bladder cancer \[[@R12]\].

On the other hand, new agents such as gemcitabine (GEM) are well adapted for intravesical instillation treatment and they are usually incorporated into systemic therapies for advanced invasive bladder cancer \[[@R13]\]. GEM is an antimetabolite pyrimidine base analogue and it has been widely used as a chemotherapeutic agent for pancreatic and lung cancer \[[@R14], [@R15]\]. Various experimental studies *in vitro* and *in vivo* have been conducted to verify the effects of GEM on bladder cancer and its efficacy has been validated in an *in vitro* model \[[@R16]\].

As suggested by published data, intravesical chemotherapies (both monotherapy and polytherapy), namely BCG, EPI, MMC and GEM, are effective for preventing TR and TP \[[@R9], [@R17]--[@R19]\]. However, a comprehensive analysis of both efficacy and safety of these therapies has not been disclosed by the current literature due to the lack of evidence. For this purpose, we designed this network meta-analysis in order to determine the relative efficacy and safety of several intravesical chemotherapies: BCG, BCG+EPI, BCG+ Isoniazid (INH), BCG+MMC, EPI, GEM and MMC.

RESULTS {#s2}
=======

Baseline characteristics of the included studies {#s2_1}
------------------------------------------------

In total 23 randomized clinical trials (RCTs) were finally included in our study after screening out irrelevant papers (Table [1](#T1){ref-type="table"}) \[[@R6], [@R20]--[@R41]\]. Among the total 5,822 subjects with follow-up periods ranging from 1 to 7.2 years, 2,399 (41.21%) individuals were treated with BCG and 1,064 (18.28%) individuals were treated with MCC (Figure [1](#F1){ref-type="fig"}). There are 2 three-arm trials and 21 two-arm trials which contain a total of seven comparisons. Moreover, there are 22 studies in which TR was assessed as the primary endpoint. TP and disease-specific mortality (DM) was assessed by 20 and 12 trials, respectively. Secondary endpoints including fever, cystitis and haematuria were researched in 9, 8 and 11 studies, respectively. The quality of included studies was assessed by using the Jadad scale ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

###### The main characteristics of included studies

  Author            Year   Follow-up (yr)   Size   Age    Male (%)   Intervention   Induction                          Outcomes                         
  ----------------- ------ ---------------- ------ ------ ---------- -------------- ---------------------------------- ---------- ----- ---- ---- ----- ----
  Solsona           2015   7.1              407    67     89.9       MMC+BCG        30 mg + 81 mg Connaught strain     44         26    10              
                                                                     BCG            81 mg Connaught strain             68         24    15              
  Gontero           2013   1                120    67.4   85.8       BCG            27 mg Connaught strain             14         3                     
                                                                     GEM            2000 mg                            16         5                     
  Järvinen          2012   7.2              68     68     80.9       MMC            \-                                 35         14    12              
                                                                     MMC+BCG        \-                                 19         8     8               
  Oosterlinck       2011   4.7              96     69     86.5       MMC+BCG        40 mg + TICE 5 × 10\^8 CFU         23         2     0               
                                                                     BCG            TICE 5 × 10\^8 CFU                 26         5     6               
  Hinotsu           2011   2                115    NR     90.4       BCG            81 mg Connaught strain             19         3                     69
                                                                     EPI            40 mg                              22         7                     
  Sylvester         2010   9.2              837    67     NR         EPI            50 mg                              147        24    19              
                                                                     BCG            TICE 5 × 10\^8 CFU                 103        19    9               
                                                                     BCG+INH        TICE 5 × 10\^8 CFU + 300 mg        110        23    10              
  Porena            2010   3.7              64     69.4   84.4       BCG            TICE 5 × 10\^8 CFU                 9          5          2          
                                                                     GEM            2000 mg                            17         10         0          
  Di Lorenzo        2010   1.3              80     70.4   61.2       GEM            2000 mg                            21         7          1          2
                                                                     BCG            81 mg Connaught strain             35         13         3          5
  Addeo             2010   3                120    66.4   85.3       MMC            40 mg                              22         10              12    4
                                                                     GEM            2000 mg                            15         6               3     2
  Cai               2008   1.3              161    NR     85.7       EPI+BCG        80 mg + TICE 5 × 10\^8 CFU         34         2                     
                                                                     BCG            TICE 5 × 10\^8 CFU                 40         4                     
  Ojea              2007   4.4              430    64.5   87         BCG            27 mg Pasteur                      88         32    8               
                                                                     MMC            30 mg                              58         141   7               
  Friedrich         2007   2.9              495    67.4   80.2       BCG            RIVM 2 × 10\^8 CFU                 41                    15         19
                                                                     MMC            20 mg                              62                    8          15
  de Reijke         2005   5.6              168    NR     92         BCG            81 mg Connaught strain             9                9    6    15    33
                                                                     EPI            50 mg                              21               13   0    7     23
  Cheng             2005   5.1              209    69.9   71.2       BCG            81 mg Connaught strain             30         9     13              
                                                                     EPI            50 mg                              59         16    7               
  Kaasinen          2003   4.7              304    70.5   80.3       MMC+BCG        40 mg                                               13              
                                                                     BCG            120 mg Connaught                                    10              
  Di Stasi          2003   3.6              108    NR     73         BCG            81 mg Pasteur                      19         6          7    24    26
                                                                     MMC            40 mg                              46         14         0    22    14
  van der Meijden   2001   3.5              957    66     77         EPI            50 mg                              142        19    12   34   82    45
                                                                     BCG            TICE 5 × 10\^8 CFU                 98         9     5    38   111   93
                                                                     BCG+INH        TICE 5 × 10\^8 CFU + 300 mg        100        15    8    72   113   78
  Bilen             2000   1.5              41     55     95.1       BCG            81 mg Connaught strain             4          2     0    3          8
                                                                     EPI+BCG        50 mg and 81 mg Connaught strain   3          1     0    2          4
  Ali-El-Dein       1999   2.5              139    58.2   77.4       EPI+BCG        50 mg and 150 mg Pasteur strain    7          3          0    18    0
                                                                     BCG            150 mg Pasteur strain              12         5          3    36    4
  Witjes            1998   7.2              344    NR     81.7       BCG            RIVM strain                        76         21    12        30    
                                                                     MMC            30 mg                              72         12    8         37    
  Rintala           1996   2.8              188    68     75.5       MMC            20--40 mg                          58         3                     
                                                                     MMC+BCG        20--40 mg                          57         3                     
  Melekos           1996   2.9              94     NR     NR         BCG            150 mg Pasteur strain              16         5               33    11
                                                                     EPI            50 mg                              22         7               12    6
  Lamm              1995   2.5              377    67     83         BCG            TICE 50 mg                         77         15    8    38   19    85
                                                                     MMC            20 mg                              101        25    12   8    19    61

\*yr: year; BCG: Bacille Calmette Guerin; MMC: Mytomicin C; GEM: Gemcitabine; EPI: Epirubicin; INH: Isoniazid; TR: tumor recurrence; TP: tumor progression; DM: disease-specific mortality.
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Pair-wise meta-analysis {#s2_2}
-----------------------

The summary odds ratios (ORs) of the corresponding outcomes (TR, TP, DM, fever, cystitis, haematuria) for each direct comparison were calculated. The results of pair-wise meta-analysis were showed in Table [2](#T2){ref-type="table"}. Patients with EPI exhibited an increased risk of TR compared to those with BCG (OR = 1.58, 95% CI = 1.23--1.90, *P* \< 0.001). By contrast, patients with BCG+MMC exhibited a significantly lower risk of TR than those with BCG (OR = 0.25, 95% CI = 0.10--0.61, *P* = 0.002). Besides that, patients with EPI or MMC exhibited a higher risk of TP than those with BCG (EPI: OR = 1.71, 95% CI = 1.16--2.53, *P* = 0.007; MMC: OR = 3.05, 95% CI = 2.24--4.17, *P* \< 0.001). Moreover, patients with MMC were associated with a reduced risk of fever compared to those with BCG (OR = 0.22, 95% CI = 0.13--0.38, *P* \< 0.001), while those with BCG + INH were associated with an increased risk of fever in relation to patients with BCG (OR = 1.92, 95% CI = 1.25--2.94, *P* = 0.003). Furthermore, both EPI (OR = 0.64, 95% CI = 0.48--0.86, *P* = 0.003) and BCG + EPI (OR = 0.44, 95% CI = 0.23--0.86, *P* = 0.016) appeared to be more effective than BCG in reducing the risk of cystitis. Finally, patients with MMC (OR = 0.55, 95% CI = 0.41--0.75, *P* = 0.011) and EPI (OR = 0.54, 95% CI = 0.39--0.74, *P* \< 0.001) were associated with approximately 45% reduction in the risk of haematuria.

###### Pair-wise meta-analyses of direct comparisons between the five drugs

  Endpoints                        Direct comparisons   *I*^2^   *P~H~* values        OR (95% CI)         *P~OR~* values
  -------------------------------- -------------------- -------- -------------------- ------------------- ----------------
  **Tumor Recurrence**             MMC vs. BCG          31.58%   0.234                1.07 (0.89, 1.29)   0.593
  GEM vs. BCG                      52.37%               0.122    1.01 (0.64, 1.61)    0.829               
  EPI vs. BCG                      0.00%                0.402    1.58 (1.32, 1.90)    **\< 0.001**        
  BCG + MMC vs. BCG                0.00%                0.058    0.25 (0.10, 0.61)    0.002               
  BCG + EPI vs. BCG                0.00%                0.672    0.76 (0.48, 1.21)    0.254               
  BCG + INH vs. BCG                0.00%                0.764    1.07 (0.85, 1.35)    0.547               
  MMC vs. GEM                      \-                   \-       1.44 (0.68. 3.07)    0.345               
  MMC vs. BCG + MMC                0.00%                0.630    1.11 (0.75, 1.64)    0.617               
  **Tumor Progression**            MMC vs. BCG          91.64%   \<.0001              3.05 (2.24, 4.17)   **\< 0.001**
  GEM vs. BCG                      42.79%               0.182    1.09 (0.55, 2.17)    0.797               
  EPI vs. BCG                      0.00%                0.351    1.71 (1.16, 2.53)    **0.007**           
  BCG + MMC vs. BCG                2.30%                0.312    0.91 (0.52, 1.59)    0.741               
  BCG + EPI vs. BCG                0.00%                0.999    0.52 (0.19, 1.44)    0.209               
  BCG + INH vs. BCG                0.00%                0.582    1.40 (0.84. 2.32)    0.193               
  MMC vs. GEM                      \-                   \-       1.64 (0.56, 4.82)    0.371               
  MMC vs. BCG + MMC                0.00%                0.852    1.17 (0.50, 2.72)    0.722               
  **Disease-specific Mortality**   MMC vs. BCG          17.96%   0.303                1.14 (0.66, 1.98)   0.634
  EPI vs. BCG                      51.78%               0.102    1.42 (0.89, 2.24)    0.324               
  BCG + MMC vs. BCG                22.63%               0.204    0.76 (0.43, 1.34)    0.335               
  BCG + EPI vs. BCG                \-                   \-       1.05 (0.06, 17.95)   0.973               
  BCG + INH vs. BCG                0.00%                0.646    1.32 (0.65, 2.69)    0.442               
  MMC vs. BCG + MMC                \-                   \-       1.05 (0.38, 2.90)    0.925               
  **Fever**                        MMC vs. BCG          0.00%    0.807                0.22 (0.13, 0.38)   **\< 0.001**
  EPI vs. BCG                      0.00%                0.813    0.40 (0.08, 2.16)    0.289               
  BCG + MMC vs. BCG                56.00%               0.132    0.83 (0.51, 1.34)    0.428               
  BCG + EPI vs. BCG                0.00%                0.565    0.49 (0.11, 2.11)    0.340               
  BCG + INH vs. BCG                \-                   \-       1.92 (1.25, 2.94)    0.003               
  **Cystitis**                     MMC vs. BCG          57.80%   0.096                0.89 (0.62, 1.27)   0.513
  EPI vs. BCG                      46.53%               0.166    0.64 (0.48, 0.86)    **0.003**           
  BCG + EPI vs. BCG                \-                   \-       0.44 (0.23, 0.86)    **0.016**           
  BCG + INH vs. BCG                \-                   \-       1.03 (0.76, 1.41)    0.839               
  MMC vs. GEM                      \-                   \-       3.93 (1.05, 14.70)   **0.042**           
  **Haematuria**                   MMC vs. BCG          66.89%   0.040                0.55 (0.41, 0.75)   0.011
  GEM vs. BCG                      \-                   \-       0.40 (0.07, 2.18)    0.290               
  EPI vs. BCG                      0.00%                0.627    0.54 (0.39, 0.74)    **0.0001**          
  BCG + EPI vs. BCG                0.00%                0.511    0.42 (0.13, 1.31)    0.135               
  BCG + INH vs. BCG                \-                   \-       0.85 (0.60, 1.20)    0.357               
  MMC vs. GEM                      \-                   \-       1.96 (0.35, 11.17)   0.447               

\*H: heterogeneity; OR: odds ratio; CI: confidence interval; BCG: Bacille Calmette Guerin; MMC: Mytomicin C; GEM: Gemcitabine; EPI: Epirubicin; INH: Isoniazid.

As suggested by Table [2](#T2){ref-type="table"}, heterogeneity among studies did not appear to be significant and thereby the fixed-effect model was incorporated in our analysis for some the comparisons. However, significant heterogeneity was presented in some comparisons (GEM vs. BCG, *I²* = 52.37%, in TR; MMC vs. BCG, *I²* = 91.64%, in TP; EPI vs. BCG, *I²* = 51.78%, in DM; BCG+MMC vs. BCG, *I²* = 56.00%, in fever; MMC vs. BCG, *I²* = 57.80%, in cystitis and MMC vs. BCG, *I²* =66.89%, in haematuria) and hence the random-effects model was implemented for these comparisons.

Network meta-analysis {#s2_3}
---------------------

Table [3](#T3){ref-type="table"} demonstrated the mixed comparisons results by synthesizing all evidence within the network. Patients with all other treatments exhibited a significantly lower risk of TR than those with EPI (OR = 0.40, 95% CrI = 0.25--0.62; OR = 0.25, 95% CrI = 0.10--0.60; OR = 0.51, 95% CrI = 0.26--0.96; OR = 0.26, 95% CrI = 0.11--0.54; OR = 0.33, 95% CrI = 0.15--0.73; OR = 0.45, 95% CrI = 0.25--0.83). On the other hand, patients with MMC exhibited experienced 84% and 91% reduction in the risk of fever compared to those treated with BCG and BCG+INH, respectively (OR = 0.16, 95% CrI = 0.04--0.50; OR = 0.09, 95% CrI = 0.01--0.97). As suggested by Figures [2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}, no significant inconsistency between direct and indirect evidence was presented with respect to TR, TP, DM or haematuria and thereby a consistent model was used in our analysis.

###### The efficacy and tolerability of seven treatments according to the network meta-analysis using odds ratios (ORs) and corresponding 95% credible intervals (CrIs)

  Tumor Recurrence                                                                                                                                 
  ----------------------- ----------------------- ----------------------- ----------------------- ------------------------ ----------------------- -----------------------
  **BCG**                 0.63 (0.28, 1.35)       1.27 (0.67, 2.49)       0.64 (0.34, 1.18)       **2.51 (1.62, 4.05)**    0.83 (0.43, 1.63)       1.14 (0.76, 1.73)
  1.59 (0.74, 3.57)       **BCG_EPI**             2.03 (0.75, 5.91)       1.02 (0.38, 2.80)       **3.98 (1.66, 10.31)**   1.34 (0.48, 3.78)       1.81 (0.77, 4.59)
  0.79 (0.40, 1.49)       0.49 (0.17, 1.34)       **BCG_INH**             0.50 (0.20, 1.20)       **1.96 (1.04, 3.82)**    0.65 (0.25, 1.61)       0.90 (0.41, 1.92)
  1.56 (0.84, 2.90)       0.98 (0.36, 2.66)       1.99 (0.83, 5.04)       **BCG_MMC**             **3.90 (1.85, 8.74)**    1.30 (0.54, 3.10)       1.78 (0.96, 3.36)
  **0.40 (0.25, 0.62)**   **0.25 (0.10, 0.60)**   **0.51 (0.26, 0.96)**   **0.26 (0.11, 0.54)**   **EPI**                  **0.33 (0.15, 0.73)**   **0.45 (0.25, 0.83)**
  1.20 (0.61, 2.35)       0.75 (0.26, 2.08)       1.54 (0.62, 4.00)       0.77 (0.32, 1.84)       **3.04 (1.36, 6.86)**    **GEM**                 1.37 (0.66, 2.83)
  0.87 (0.58, 1.31)       0.55 (0.22, 1.30)       1.12 (0.52, 2.42)       0.56 (0.30, 1.04)       **2.20 (1.20, 4.04)**    0.73 (0.35, 1.51)       **MMC**

  Tumor Progression                                                                                                            
  -------------------- ------------------- -------------------- -------------------- -------------------- -------------------- --------------------
  **BCG**              0.46 (0.06, 3.07)   1.73 (0.27, 10.98)   1.16 (0.22, 5.92)    2.23 (0.60, 8.60)    1.35 (0.29, 6.27)    2.69 (0.80, 8.99)
  2.19 (0.33, 17.18)   **BCG_EPI**         3.75 (0.26, 58.16)   2.57 (0.18, 36.01)   4.89 (0.49, 54.05)   3.01 (0.24, 36.91)   5.92 (0.60, 62.73)
  0.58 (0.09, 3.70)    0.27 (0.02, 3.87)   **BCG_INH**          0.69 (0.05, 7.84)    1.31 (0.20, 8.01)    0.79 (0.07, 8.40)    1.59 (0.17, 14.16)
  0.86 (0.17, 4.63)    0.39 (0.03, 5.42)   1.45 (0.13, 18.85)   **BCG_MMC**          1.89 (0.25, 16.30)   1.15 (0.14, 10.37)   2.31 (0.45, 12.15)
  0.45 (0.12, 1.67)    0.20 (0.02, 2.03)   0.76 (0.12, 4.91)    0.53 (0.06, 4.04)    **EPI**              0.61 (0.08, 4.36)    1.19 (0.20, 6.98)
  0.74 (0.16, 3.45)    0.33 (0.03, 4.19)   1.26 (0.12, 14.80)   0.87 (0.10, 7.31)    1.64 (0.23, 12.63)   **GEM**              1.99 (0.32, 11.86)
  0.37 (0.11, 1.25)    0.17 (0.02, 1.65)   0.63 (0.07, 5.75)    0.43 (0.08, 2.23)    0.84 (0.14, 5.06)    0.50 (0.08, 3.09)    **MMC**

  Disease-specific Mortality                                                                                        
  ---------------------------- --------------------- -------------------- -------------------- -------------------- --------------------
  **BCG**                      0.94 (0.02, 62.49)    1.02 (0.34, 3.21)    0.66 (0.24, 1.50)    1.45 (0.61, 3.36)    1.04 (0.44, 2.39)
  1.06 (0.02, 50.15)           **BCG_EPI**           1.08 (0.01, 58.75)   0.67 (0.01, 33.01)   1.51 (0.02, 77.52)   1.06 (0.01, 53.12)
  0.98 (0.31, 2.95)            0.93 (0.02, 71.92)    **BCG_INH**          0.65 (0.13, 2.41)    1.41 (0.45, 4.02)    1.02 (0.22, 4.01)
  1.52 (0.67, 4.24)            1.49 (0.03, 108.70)   1.54 (0.41, 7.68)    **BCG_MMC**          2.19 (0.68, 8.20)    1.56 (0.58, 5.14)
  0.69 (0.30, 1.63)            0.66 (0.01, 46.96)    0.71 (0.25, 2.20)    0.46 (0.12, 1.48)    **EPI**              0.72 (0.22, 2.37)
  0.96 (0.42, 2.30)            0.94 (0.02, 66.73)    0.98 (0.25, 4.45)    0.64 (0.19, 1.73)    1.40 (0.42, 4.63)    **MMC**

  Fever                                                                                                              
  ------------------------ -------------------- -------------------------- -------------------- -------------------- -----------------------
  **BCG**                  0.40 (0.04, 2.88)    1.87 (0.23, 10.82)         0.61 (0.08, 2.16)    0.33 (0.03, 2.78)    **0.16 (0.04, 0.50)**
  2.48 (0.35, 23.42)       **BCG_EPI**          4.39 (0.26, 71.94)         1.40 (0.08, 18.35)   0.78 (0.04, 17.48)   0.40 (0.03, 4.84)
  0.54 (0.09, 4.42)        0.23 (0.01, 3.89)    **BCG_INH**                0.32 (0.04, 1.89)    0.18 (0.01, 3.79)    **0.09 (0.01, 0.97)**
  1.64 (0.46, 12.65)       0.71 (0.05, 12.55)   3.10 (0.53, 26.47)         **EPI**              0.57 (0.04, 11.29)   0.26 (0.04, 2.67)
  3.02 (0.36, 37.16)       1.29 (0.06, 28.39)   5.68 (0.26, 109.10)        1.76 (0.09, 26.83)   **GEM**              0.48 (0.04, 7.08)
  **6.31 (2.01, 25.05)**   2.50 (0.21, 29.69)   **11.60 (1.03, 123.98)**   3.78 (0.37, 23.27)   2.06 (0.14, 27.16)   **MMC**

  Cystitis                                                                                                  
  --------------------- -------------------- -------------------- -------------------- -------------------- ---------------------
  **BCG**               0.68 (0.16, 2.59)    0.13 (0.01, 2.32)    0.34 (0.08, 1.31)    0.22 (0.02, 2.31)    0.79 (0.08, 6.14)
  1.47 (0.39, 6.09)     **MMC**              0.19 (0.01, 2.49)    0.49 (0.07, 3.74)    0.32 (0.02, 5.47)    1.13 (0.08, 13.65)
  7.72 (0.43, 159.74)   5.23 (0.40, 79.26)   **GEM**              2.59 (0.10, 71.24)   1.69 (0.04, 79.64)   5.95 (0.15, 231.17)
  2.97 (0.76, 12.83)    2.03 (0.27, 15.33)   0.39 (0.01, 9.53)    **EPI**              0.65 (0.04, 11.41)   2.31 (0.27, 19.31)
  4.56 (0.43, 47.81)    3.13 (0.18, 48.99)   0.59 (0.01, 23.00)   1.54 (0.09, 23.08)   BCG+EPI              3.49 (0.13, 80.12)
  1.27 (0.16, 12.04)    0.88 (0.07, 12.54)   0.17 (0.00, 6.87)    0.43 (0.05, 3.76)    0.29 (0.01, 7.99)    **BCG + INH**

  Haematuria                                                                                                
  --------------------- -------------------- -------------------- -------------------- -------------------- ---------------------
  **BCG**               0.31 (0.04, 2.28)    0.21 (0.01, 4.65)    0.19 (0.02, 1.17)    0.27 (0.01, 5.02)    0.55 (0.02, 16.14)
  3.22 (0.44, 26.17)    **MMC**              0.68 (0.03, 15.37)   0.60 (0.03, 9.25)    0.85 (0.02, 32.72)   1.80 (0.03, 94.56)
  4.75 (0.21, 104.85)   1.46 (0.07, 33.05)   **GEM**              0.87 (0.02, 27.84)   1.23 (0.02, 99.40)   2.61 (0.03, 233.17)
  5.37 (0.86, 41.23)    1.66 (0.11, 29.78)   1.15 (0.04, 46.72)   **EPI**              1.43 (0.05, 53.28)   3.00 (0.10, 96.15)
  3.76 (0.20, 80.76)    1.18 (0.03, 45.96)   0.81 (0.01, 64.93)   0.70 (0.02, 20.87)   **BCG + EPI**        2.09 (0.02, 194.73)
  1.82 (0.06, 57.61)    0.56 (0.01, 28.65)   0.38 (0.00, 35.66)   0.33 (0.01, 9.75)    0.48 (0.01, 45.77)   **BCG + INH**

\*BCG: Bacille Calmette Guerin; MMC: Mytomicin C; GEM: Gemcitabine; EPI: Epirubicin; INH: Isoniazid.
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The estimated probabilities and their corresponding SUCRA are displayed in Figure [6](#F6){ref-type="fig"}. Incorporating EPI or MMC into BCG (EPI+BCG, MMC+BCG) appeared to be the most preferred interventions with respect to TR, TP and DM. As for fever, cystitis and haematuria, BCG+EPI also exhibited a satisfied SUCRA value. Overall, incorporating EPI or MMC into BCG (EPI+BCG, MMC+BCG) was potentially more preferable than others when all of the six endpoints were taken into account.

![The corresponding results of SUCRA with respect to six endpoints (A) tumor recurrence; (B) tumor progression; (C) disease-specific mortality; (D) fever; (E) cystitis; (F) haematuria](oncotarget-07-82567-g006){#F6}

DISCUSSION {#s3}
==========

Instillation therapy with BCG has been considered as the standard treatment for patients with NMIBC \[[@R42]\]. The limitation of BCG motivates researchers to seek alternative chemotherapeutic agents that may have equivalent efficacy. We extracted data from 23 studies which incorporate a total of seven bladder intravesical instillation methods for NMIBC patients. Our objective is to determine whether these approaches have comparable efficacy with an increased safety and tolerability level. Direct evidence from conventional meta-analysis indicates that BCG is more preferred than EPI with respect to TR and TP. On the other hand, our network-meta analysis indicates that EPI is the worst with respect to TR. As shown by the corresponding ranking based on SUCRA values, both BCG + EPI and BCG + MMC have superior performance in comparison to other bladder intravesical instillations.

Adjuvant instillation of BCG has been verified as the most effective intravesical therapy that is able to prevent TR and progression \[[@R43]--[@R45]\]. Studies have concluded that the TR rate and TP rate can range from 23% to 49% and 4.8% to 25.6% over a five-year period among patients with intermediate and high-risk NMIBC \[[@R46], [@R47]\]. Furthermore, several studies reported that maintenance instillation of BCG is more effective than both chemotherapy and BCG monotherapy with respect to recurrence prevention for NMIBC patients \[[@R44], [@R48], [@R49]\]. However, maintenance instillation of BCG is not recommended for all NMIBC patients due to potential side effects \[[@R47]\].

EPI (4′-epidoxorubicin) is an antineoplastic agent which is derived from doxorubicin and it exerts antitumor effects by affecting DNA synthesis and such a mechanism is stimulated during the S phase of the cell cycle \[[@R50]\]. EPI has very limited effectiveness because it is a single chemotherapy agent against tumors and its effectiveness can be enhanced if combined with other chemotherapy agents \[[@R50]\]. A common conclusion obtained from both network-meta analysis and the ranking based on SUCRA values is that introducing BCG into EPI appears to be more effective than EPI monotherapy and this strategy is associated with a decrease in the risk of TR.

MMC is another chemotherapy agent which also inhibits DNA synthesis and there is no consensus about the difference between BCG+MMC and BCG monotherapy with respect to preventing TR and TP \[[@R51], [@R52]\]. Results from direct evidence showed that BCG + MMC are more effective than BCG monotherapy, and such a conclusion is supported by indirect evidence. Taking TR, TP and DM into consideration, BCG + MMC have several strengths with respect to these endpoints. A recent study also found that BCG + MMC appeared to be more effective than BCG or MMC monotherapy (5-year TR rate: 20.6% vs. 33.9%) \[[@R45]\].

The SUCRA ranking plot suggests that GEM may exhibit a safety profile with respect to the risk of fever, cystitis and haematuria. However, this trend is not reflected by our pairwise or network meta-analysis. We suspect this inconsistency for several reasons. Firstly, there may exit significant study heterogeneity which potentially causes the inconsistency between direct and indirect evidence. Secondly, the corresponding SUCRA values were produced by using the Bayesian Framework in conjunction with the MCMC sampling technique. Compared to the frequentist approach, the Bayesian framework does not lead to an unbiased estimator and such a characteristic may be reflected in the SUCRA values. The current literature indicates that GEM pyrimidine antimetabolite with approved efficacy and mild toxicity \[[@R53]\]. Nevertheless, the safety of GEM should be warranted in the future if it is used as a monotherapy or polytherapy for bladder patients. On the other hand, the current literature suggests that INH could cause chronic liver dysfunction and its application is restricted in clinical practices \[[@R27], [@R54]\] and our results also showed a worse performance of BCG + INH in TR.

This study is the first Bayesian network meta-analysis which simultaneously compares seven bladder intravesical instillation methods for patients with NMIBC. However, there are still some limitations affecting the results of our analysis. On one hand, there are large deviations in the sample size among different studies and such unbalanced sample size may have significant influence on the overall conclusions. On the other hand, we only analyzed the short-term effects of intravesical instillation methods on NMIBC patients due to the lack of evidence and thereby prognoses like survival rate of these approaches are still unclear.

In conclusion, combined intravesical instillation methods such as BCG + EPI and BCG + MMC exhibited outstanding efficacy for NIMBC patients. Nevertheless, future studies should further investigate the long-term effects of these intravesical instillation methods on NMIBC patients and the selection of appropriate methods should be validated by using well designed trials.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Randomized control trials (RCTs) with "Bacillus Calmette - Guerin" or "mytomicin C" or "gemcitabine" or "epirubicin" or "isoniazid" matched with "bladder Cancer" was searched in PubMed, Embase, China National Knowledge Internet (CNKI), which were update to April, 2016 without any restriction on language. A manual search was also performed on the reference list of each relevant study, previous meta-analyses and earlier reviews of intravesical instillation therapies in relation to bladder tumor so that inappropriate omission can be prevented. The literature searching and retrieving process were carried out by two reviewers independently. All the arguments were solved by a third reviewer.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Studies are eligible if: (1) their sample size were greater than 30 and (2) belonged to Randomized control trials (RCTs); (3) patients were above 18 years old and pathologically diagnosed with bladder cancer; (4) the efficacy of two or more intravesical instillation therapies (BCG, MMC, GEM, EPI, INH) were compared; (5) sufficient outcome data were provided. Articles are excluded if: (1) patients had history of muscle-invasive disease, upper urinary tract tumor or chronic urinary tract infection; (2) patients had other disease with immunodeficiency. The literature search, screen and selection flow chart was shown in [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}.

Outcome measures and data extraction {#s4_3}
------------------------------------

The following data was extracted from eligible studies, including gender, age, sample size, duration of follow-up, treatment and dosage. The effectiveness and tolerability of intravesical instillation therapies were assessed by using multiple endpoints including TR, TP, DM, fever, cystitis and haematuria. Data extraction was performed by two reviewers independently. Risk of complications such as fever, cystitis and haematuria were considered as secondary outcomes which evaluated the tolerability of intravesical instillation therapies.

Statistical analysis {#s4_4}
--------------------

Conventional pair-wise meta-analysis was initially carried out and it incorporates direct evidence for each pair of treatment comparison. The fixed-effect model or random-effects model was implemented in pair-wise meta-analysis and the odds ratios (ORs) with their corresponding 95% confidence intervals (CI) were pooled in order to produce a summary effect size for each endpoint. Heterogeneity among studies was assessed by using the statistic of *I*^2^ and Q. No significant heterogeneity was suggested if *P* \> 0.05 or *I*^2^ \< 50% and thereby a fixed-effect model was selected. Otherwise, a random-effects model was taken into account due to the presence of significant heterogeneity.

Next, we carried out a network meta-analysis which is based on the Bayesian framework using R 3.2.3 software. Both direct and indirect evidence were synthesized from selected studies in order to produce summary statistics for each endpoint. Aside from that, intravesical instillation interventions are ranked by using the surface under the cumulative ranking curve (SUCRA) which produces a comprehensive ranking with respect to each endpoint. The corresponding ranking probabilities were defined as cumulative probabilities that each treatment being ranked as the first, second and so on. The larger SUCRA values, the more preferred ranking for each intravesical instillation intervention.
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